Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 9/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056614 | 0.85 | TSHR (0.57) | TSHRCYP3A4ALDH1A1RECQLSMN1; SMN2 | |
| SCHEMBL1265339 | 0.83 | TSHR (0.55) | TSHRCYP3A4ALDH1A1RECQLSMN1; SMN2 | |
| SCHEMBL30711152 | 0.83 | TSHR (0.55) | TSHRCYP3A4ALDH1A1RECQLSMN1; SMN2 | |
| SCHEMBL2056814 | 0.83 | TSHR (0.60) | TSHRCYP3A4ALDH1A1RECQLSMN1; SMN2 | |
| SCHEMBL11599278 | 0.82 | TSHR (0.55) | TSHRCYP3A4ALDH1A1RECQLSMN1; SMN2 | |
| SCHEMBL27293483 | 0.81 | ALDH1A1 (0.57) | TSHRCYP3A4ALDH1A1RECQLSMN1; SMN2 | |
| SCHEMBL3192674 | 0.80 | TSHR (0.65) | TSHRCYP3A4ALDH1A1RECQLSMN1; SMN2 | |
| SCHEMBL5313608 | 0.80 | TSHR (0.52) | TSHRCYP3A4ALDH1A1RECQLSMN1; SMN2 | |
| SCHEMBL16599621 | 0.80 | TSHR (0.52) | TSHRCYP3A4ALDH1A1RECQLSMN1; SMN2 | |
| SCHEMBL241906 | 0.80 | ALDH1A1 (0.47) | TSHRCYP3A4ALDH1A1RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6372030-B1 | INK VEHICLE SELECTED FROM 4-(HEXADECYLAMINO)BENZYLAMINE, N-OCTANOYL-N-METHYL GLUCAMINE, OCTANOIC HYDRAZIDE, 4-HEXADECYL SULFONYL ANILINE, A CONDUCTIVE COMPLEX OF AN AMINE COMPOUND WITH A PHOSPHORUS OR SULFUR-CONTAINING ACID | XEROX CORPORATION | 2002-04-16 | — | — | US | claimed |
| EP-0377112-B1 | Quinoxaline compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-08-24 | — | — | EP | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2025077716-A1 | PKMYT1 INHIBITORY COMPOUND AND USE THEREOF | 杭州中美华东制药有限公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | INNOVATION INSTITUTE FOR ARTIFICIAL INTELLIGENCE IN MEDICINE OF ZHEJIANG UNIVERSITY (CN) | 2025-03-27 | — | — | US | disclosed |
| US-20240408216-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2024-12-12 | — | — | US | disclosed |
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-10-17 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4382514-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2024-06-12 | — | — | EP | disclosed |
| CN-118139847-A | Pyrimidine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2024-06-04 | — | — | CN | disclosed |
| EP-0537611-A1 | Process for the preparation of substituted N-(aryl)-1,2,4-triazolopyrimidine-2-sulfonamides | DOWELANCO (US) | 1993-04-21 | — | — | EP | disclosed |
| US-5177206-A | Process for the preparation of substituted N-(aryl)-1,2,4-triazolopyrimidine-2-sulfonamides | DOWELANCO (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0511826-A2 | Phosphosulfonate herbicides | ROHM AND HAAS COMPANY (US) | 1992-11-04 | — | — | EP | disclosed |
| US-5061706-A | 2,3-QUINOXALINEDIONES FOR USE AS NEUROLEPTICS | NOVO NORDISK A/S (DK) | 1991-10-29 | — | — | US | disclosed |
| US-4818753-A | FUNGICIDES; SYNERGISTIC EFFECT WITH SULFA DRUGS | SRI INTERNATIONAL (US) | 1989-04-04 | — | — | US | disclosed |
| US-4668686-A | 1,3-DIHYDRO-2H-IMIDAZO/4,5-B/QUINOLINE-2-ONES | BRISTOL-MYERS COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| US-4009994-A | Process and product of optical brightening with quaternized benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1977-03-01 | — | — | US | disclosed |
| US-3940417-A | Quaternised benzofuranyl-benzimidazoles | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
| US-3931215-A | OPTICAL BRIGHTENERS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | EGFR, BLK, CSNK1A1L | TSHR 3467/4885CYP3A4 1367/4885ALDH1A1 4631/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | TSHR 4213/4885CYP3A4 4044/4885ALDH1A1 1816/4885 |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | EGFR, ERBB2, ERBB3 | TSHR 973/4885CYP3A4 1197/4885ALDH1A1 2593/4885 |
| US-20240408216-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | PSME1, IDE, PRUNE1 | TSHR 4621/4885CYP3A4 1655/4885ALDH1A1 4213/4885 |
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | ERBB2, EGFR, DPYD | TSHR 3561/4885CYP3A4 1621/4885ALDH1A1 1991/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | TSHR 4393/4885CYP3A4 3974/4885ALDH1A1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.